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INTRODUCTION
Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired
clonal hematopoietic stem cell disorder that manifests as hemo-
lytic anemia, venous thrombosis, and cytopenia. Although
allogeneic stem cell transplantation (allo-SCT) is considered
the only curative treatment, this treatment is associated with
high treatment-related mortality (1, 2). Non-myeloablative
stem cell transplantation (NST) uses reduced intensity con-
ditioning regimens to decrease regimen-related toxicity and
is used in patients who are not eligible for myeloablative stem
cell tranplsantation due to advanced age or medically debilitat-
ed patients unable to tolerate myeloablative conditioning
regimen (3, 4). Recently there was a case report of a patient
with PNH who underwent NST (5). However, further studies
are needed to establish the role of allo-SCT, especially reduced
intensity conditioning therapy and its incidence of graft-versus-
host disease (GVHD), in the treatment of PNH.
Chronic GVHD is one of the most frequent complications
after both myeloablative allo-SCT and NST (3, 4). Giralt et
al. (6) reported that actuarial risk of chronic GVHD was 68
±9% in 86 patients who had undergone NST due to a vari-
ety of hematologic malignancies and poor candidates for con-
ventional myeloablative allo-SCT. It is immune-mediated and
involves autoantibodies generated by donor T-lymphocyte
reactivity to major histocompatibility complex (MHC) anti-
gens (7, 8). Many of the features seen in chronic GVHD are
similar to various immune complex disorders such as collagen
vascular disease. Although glomerular disease has been describ-
ed as one of the rare manifestations of chronic GVHD fol-
lowing the usual myeloablative allo-SCT (9-18) and murine
GVHD has been studied as a model of lupus nephritis (19),
membranous glomerulopathy as a manifestation of chronic
GVHD after allo-SCT is particularly unusual.
We describe a patient who underwent non-myeloablative
allo-SCT for PNH and received cyclosporine A as GVHD
prophylaxis. After 25 months of allo-SCT, she developed ne-
phrotic syndrome following extensive chronic GVHD.
CASE REPORT
A 22-yr-old woman with PNH underwent non-myeloab-
lative stem cell transplantation from an HLA-matched sibling
donor (her younger sister) in December 1999 because of refrac-
tory hemolysis and aggravating cytopenia. She received Bu-
Fludara-ATG (busulfan 4 mg/kg/day for 2 days, fludarabine
30 mg/m2/day for 6 days, and ATG 20 mg/kg/day for 4 days)
for conditioning therapy and G-CSF mobilized peripheral
blood stem cells. Cyclosporin A (CsA) alone was administered
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Allogeneic stem cell transplantation (allo-SCT) using related or unrelated donor
could eradicate paroxysmal nocturnal hemoglobinuria (PNH) clones and may cure
the disease. Chronic graft-versus host disease (GVHD) is a major complication
of patients who have undergone allo-SCT. Nephrotic syndrome has been described
as one of the rare manifestations of chronic GVHD following the usual myeloabla-
tive allo-SCT. We report a case of nephrotic syndrome that developed 25 months
after non-myeloablative allo-SCT for PNH. The patient had grade II acute GVHD
and extensive chronic GVHD after non-myeloablative allo-SCT. Typically the patient
presented with preserved renal function and full nephrotic syndrome including gen-
eralized edema, proteinuria, hypoalbuminemia, and hypercholesterolemia. Renal
biopsy revealed findings of membranous glomerulopathy (MG). The patient is alive
with a stable engraftment and full donor chimerism under the administration of
tacrolimus for control of chronic GVHD and MG without refractory hemolysis and
cytopenia.
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for GVHD prophylaxis. An erythematous maculopapular skin
lesion developed on the 45th day of post-stem cell transplan-
tation as a manifestation of acute GVHD; stage II skin lesion;
with no evidence of jaundice or gastrointestinal involvement.
Skin biopsy revealed interface dermatitis consistent with
GVHD. After improvement of the skin lesion, CsA was ta-
pered from 90 days after stem cell transplantation and was
withdrawn after 140 days. After 1 week, the patient presented
with an erythematous maculopapular rash on trunk and upper
and lower extremities, a dry mouth, and conjunctival hyper-
emia. Opthalmological evaluation confirmed GVHD syn-
drome involving both eyes as a sicca-like syndrome. Methyl-
prednisolone (Methyl-pd) was administered for treatment of
extensive chronic GVHD. 
In February 2002, the patient presented with edema, hema-
turia, proteinuria, and hypoalbuminemia. Proteinuria pro-
gressed to the nephrotic range and the patient was admitted
to the hospital. On admission, blood pressure was normal and
skin rash, jaundice and gastrointestinal symptoms were absent.
Results of hematologic studies were normal. Laboratory data
indicated the presence of nephrotic syndrome, with proteinuria
of 3.6 g/day, serum total protein 4.1 g/dL, serum albumin
2.5 g/dL, BUN 16 mg/dL, creatinine 0.7 mg/dL, and total
cholesterol 254 mg/dL. Urinalysis indicated a red blood cell
count of 21 to 30 cells/HPF with pyuria. Creatinine clearance
was 116 mL/min. Antinuclear antibody, anti-ds DNA, cryo-
globulin, and hypocomplementemia were not present. Tests
for the hepatitis B virus surface antigen and antibody and the
hepatitis C antibody showed negative results. Two cores of
renal cortex and medulla contained 13 glomeruli, one of which
was globally sclerotic under light microscopy. The mesangium
was moderately expanded due to the increase in the matrix
with focal hypercellularity. Microscopic findings were com-
patible with MG (Fig. 1, 2)
Treatment with tacrolimus was initiated and close follow-up
was scheduled. The patient is well with a stable engraftment
and full donor chimerism and does not have any evidence of
nephrotic syndrome from the treatment with tacrolimus alone.
She is still on regular follow-up at the outpatient clinic. 
DISCUSSION
We described a patient who had undergone non-myeloab-
lative allo-SCT for PNH and received CsA as GVHD prophy-
laxis. She experienced an erythematous maculopapular rash,
aggravation of liver function, and conjunctivitis-sicca syndrome
A B
Fig. 1. Membranous glomerulonephropathy. (A) Light micrograph (×200, PAS stain) reveals minimal glomerular changes with focal tubular
atrophy, mild interstitial fibrosis and mild diffuse thickening of glomerular basement membrane without evidence of Inflammation or cellular
proliferation consistent with membranous nephropathy. (B) Immunofluorescence (C3, ×100) demonstrats granular deposition of C3 along
glomerular capillary wall and disclosed a 1+ peripheral granular diffuse positivity for IgG.
Fig. 2. Membraneous glomerulonephropathy: electron micrograph
shows dense subepithelial immune deposits and diffuse effacement
of the foot processes of epithelial cells consistent with membranous
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after CsA withdrawal as her first manifestation of chronic
GVHD. After 25 months of non-myeloablative allo-SCT,
diagnosis of membranous glomerulopathy was diagnosed by
a kidney biopsy.
In the setting of chronic GVHD following allogeneic stem
cell transplantation, possible etiologies of generalized edema
and hypoalbuminemia include hepatic dysfunction, intractable
diarrhea, and other debilitating infectious diseases. Renal insult
following allo-SCT can be due to several conditions such as
CsA, TBI, and other nephrotoxic agents (20). In our patient,
TBI was not incorporated in the conditioning regimen. CsA
was not used at presentation, and the biopsy findings were not
compatible with CsA toxicity. In addition, there was no history
of a nephrotoxic drug in our patient.
The present case differs from those in other reports (9-18)
in several ways; this is the first case of membranous glomeru-
lonephropathy associated with chronic GVHD that developed
following non-myeloablative allo-SCT. Second, PNH is not
a common hematologic disease where allo-SCT is indicated.
There are supportive data of the relationship between GVHD
and the development of MG. GVHD is a condition in which
donor T cells become reactive against the major or minor his-
tocompatibility antigens of the hosts. Therefore, a change of
glomerular permeability may occur through the cytokine
release of donor T-lymphocytes (21). Although approximately
one quarter of patients who undergo allo-SCT do not develop
GVHD, all patients developing MG after allo-SCT had evi-
dence of GVHD. This finding suggests that GVHD is closely
related to MG. MG associated with GVHD has similarities
with de novo MG occurring in the renal allograft. In both
settings, the development of MG is associated with allogeneic
tissue transplantation and immunosuppression with agents
such as CsA. A proposed mechanism for de novo MG involves
host alloreactivity to donor MHC or non-MHC antigens
expressed on glomerular podocytes. The activity could be
demonstrated experimentally by antibody to angiotensin-con-
verting enzyme in a porcine model (22). The observation that
de novo MG occurs only in the transplanted kidney, sparing
the native kidney, strongly supports the mechanism of host-
antibody formation to locally expressed donor alloantigen (23).
In conclusion, glomerular diseases such as MG should be
considered as a manifestation of chronic GVHD in all patients
with hypoalbuminemia, proteinuria, and edema following
allo-SCT. Further investigation is needed to further elucidate
the pathogenesis and relationship between GVHD and MG.
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